中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2011年
5期
393-396
,共4页
温赤君%朱明风%任文美%刘笑迎%钱红
溫赤君%硃明風%任文美%劉笑迎%錢紅
온적군%주명풍%임문미%류소영%전홍
哮喘%鼻炎,变应性,常年性%粉尘螨%脱敏法,免疫
哮喘%鼻炎,變應性,常年性%粉塵螨%脫敏法,免疫
효천%비염,변응성,상년성%분진만%탈민법,면역
Asthma%Rhinitis,allergic,perennial%Dermatophagoides farinae%Desensitization,immunologic
目的 探讨舌下含服标准化粉尘螨变应原疫苗治疗儿童支气管哮喘伴变应性鼻炎的有效性和安全性.方法 采用前后自身对照,比较52例年龄4～14岁粉尘螨过敏的支气管哮喘伴变应性鼻炎患儿治疗前及免疫治疗1年、2年后的症状评分、药物评分以及不良反应发生率,评价其疗效和安全性.以SPSS 17.0软件对数据进行统计学分析.结果 治疗前患儿支气管哮喘日间、夜间的症状评分分别为(3.22±0.66)、(2.05±0.57)分,治疗后1年分别为(1.68±0.61)、(0.94±0.32)分,治疗后2年分别为(0.61±0.28)、(0.43±0.13)分,治疗后1年较治疗前明显降低,治疗后2年较治疗后1年明显降低.差异均有统计学意义(q值分别为15.25、13.78、10.29、6.07,P值均<0.01).治疗前患儿变应性鼻炎的症状评分及药物评分分别为(2.34±0.59)、(3.09±1.01)分,治疗后1年分别为(1.21±0.46)、(1.89±0.64)分,差异有统计学意义(q值分别为15.48、18.61,P值均<0.01);治疗后2年分别为(1.02±0.37)、(1.49±0.38)分,与治疗后1年相比筹异无统计学意义(q值分别为2.53、2.78,P值均>0.05).治疗过程中未发生严重不良事件,仅表现为口腔不适感.结论 标准化粉尘螨变应原疫苗舌下含服是一种治疗儿童粉尘螨支气管哮喘伴变应性鼻炎的安全有效方法.
目的 探討舌下含服標準化粉塵螨變應原疫苗治療兒童支氣管哮喘伴變應性鼻炎的有效性和安全性.方法 採用前後自身對照,比較52例年齡4～14歲粉塵螨過敏的支氣管哮喘伴變應性鼻炎患兒治療前及免疫治療1年、2年後的癥狀評分、藥物評分以及不良反應髮生率,評價其療效和安全性.以SPSS 17.0軟件對數據進行統計學分析.結果 治療前患兒支氣管哮喘日間、夜間的癥狀評分分彆為(3.22±0.66)、(2.05±0.57)分,治療後1年分彆為(1.68±0.61)、(0.94±0.32)分,治療後2年分彆為(0.61±0.28)、(0.43±0.13)分,治療後1年較治療前明顯降低,治療後2年較治療後1年明顯降低.差異均有統計學意義(q值分彆為15.25、13.78、10.29、6.07,P值均<0.01).治療前患兒變應性鼻炎的癥狀評分及藥物評分分彆為(2.34±0.59)、(3.09±1.01)分,治療後1年分彆為(1.21±0.46)、(1.89±0.64)分,差異有統計學意義(q值分彆為15.48、18.61,P值均<0.01);治療後2年分彆為(1.02±0.37)、(1.49±0.38)分,與治療後1年相比籌異無統計學意義(q值分彆為2.53、2.78,P值均>0.05).治療過程中未髮生嚴重不良事件,僅錶現為口腔不適感.結論 標準化粉塵螨變應原疫苗舌下含服是一種治療兒童粉塵螨支氣管哮喘伴變應性鼻炎的安全有效方法.
목적 탐토설하함복표준화분진만변응원역묘치료인동지기관효천반변응성비염적유효성화안전성.방법 채용전후자신대조,비교52례년령4～14세분진만과민적지기관효천반변응성비염환인치료전급면역치료1년、2년후적증상평분、약물평분이급불량반응발생솔,평개기료효화안전성.이SPSS 17.0연건대수거진행통계학분석.결과 치료전환인지기관효천일간、야간적증상평분분별위(3.22±0.66)、(2.05±0.57)분,치료후1년분별위(1.68±0.61)、(0.94±0.32)분,치료후2년분별위(0.61±0.28)、(0.43±0.13)분,치료후1년교치료전명현강저,치료후2년교치료후1년명현강저.차이균유통계학의의(q치분별위15.25、13.78、10.29、6.07,P치균<0.01).치료전환인변응성비염적증상평분급약물평분분별위(2.34±0.59)、(3.09±1.01)분,치료후1년분별위(1.21±0.46)、(1.89±0.64)분,차이유통계학의의(q치분별위15.48、18.61,P치균<0.01);치료후2년분별위(1.02±0.37)、(1.49±0.38)분,여치료후1년상비주이무통계학의의(q치분별위2.53、2.78,P치균>0.05).치료과정중미발생엄중불량사건,부표현위구강불괄감.결론 표준화분진만변응원역묘설하함복시일충치료인동분진만지기관효천반변응성비염적안전유효방법.
Objective To study the clinical efficacy of sublingual immunotherapy using standardized dermatophagoides farinae extract for children with combined allergic rhinitis and asthma syndrome. Methods Fifty-two children, from 4 to 14 years of age, with mite-sensitive combined allergic rhinitis and asthma syndrome were treated sublingually with standardized dermatophagoides farinae extract. The clinical efficacy was evaluated by monthly follow-up visits. After treatment for 1 or 2 years using the standardized dermatophagoides farinae extract, the asthma and rhinitis symptom scores, medication scores and adverse reactions before and after treatment were evaluated. SPSS 17.0 software was used to analyze the data. Results The allergic asthma symptom scores before treatment during the day were 3. 22 ±0. 66 and at night 2.05 ±0. 57. After 1 year of treatment, the day and night scores ( 1. 68 ± 0. 61 , 0. 94 ± 0. 32) respectively, were decreased significantly (q values were 15. 25 and 13. 78 respectively, all P < 0. 01 ). After 2 years of treatment, the scores (0. 61 ± 0. 28, 0. 43 ±0. 13 ) were also decreased significantly ( q values were 10. 29 and 6. 07 respectively, all P < 0. 01 ). The allergic rhinitis symptom scores and medication scores were 2. 34 ± 0. 59 and 3. 09 ±1.01 respectively before treatment and 1.21 ± 0. 46 and 1. 89 ±0. 64 after 1 year of treatment. The differences were significant ( q values were 15. 48 and 18. 61 respectively, all P<0.01). The allergic rhinitis symptom scores and medication scores were 1.02 ±0.37 and 1.49 ± 0. 38 after 2 years of treatment. There was no significant difference between 2 years of treatment and 1 year of treatment(q values were 2.53 and 2.78 respectively, all P >0.05). There were no severe adverse events during the treatment, except for mild mouth cavity discomfort. Conclusions Suhlingual immunotherapy using standardized dermatophagoides farinae extract is safe and effective in the treatment ofchildren with combined allergic rhinitis and asthma syndrome.
